| 1XMI |
2.25 |
Crystal structure of human F508A NBD1 domain with ATP |
| 1XMJ |
2.3 |
Crystal structure of human deltaF508 human NBD1 domain with ATP |
| 2BBO |
2.55 |
Human NBD1 with Phe508 |
| 2BBS |
2.05 |
Human deltaF508 NBD1 with three solubilizing mutations |
| 2BBT |
2.3 |
Human deltaF508 NBD1 with two solublizing mutations. |
| 2LOB |
|
PDZ Domain of CAL (Cystic Fibrosis Transmembrane Regulator-Associated Ligand) |
| 2PZE |
1.7 |
Minimal human CFTR first nucleotide binding domain as a head-to-tail dimer |
| 2PZF |
2.0 |
Minimal human CFTR first nucleotide binding domain as a head-to-tail dimer with delta F508 |
| 2PZG |
1.8 |
Minimal human CFTR first nucleotide binding domain as a monomer |
| 3GD7 |
2.7 |
Crystal structure of human NBD2 complexed with N6-Phenylethyl-ATP (P-ATP) |
| 3ISW |
2.8 |
Crystal structure of filamin-A immunoglobulin-like repeat 21 bound to an N-terminal peptide of CFTR |
| 4WZ6 |
2.05 |
Human CFTR aa389-678 (NBD1), deltaF508 with three solubilizing mutations, bound ATP |
| 5D2D |
2.1 |
Crystal structure of human 14-3-3 zeta in complex with CFTR R-domain peptide pS753-pS768 |
| 5D3E |
2.75 |
Crystal structure of human 14-3-3 gamma in complex with CFTR R-domain peptide pS768-pS795 |
| 5D3F |
2.74 |
Crystal structure of human 14-3-3 zeta in complex with CFTR R-domain peptide pS753-pS768 and stabilizer fusicoccin-A |
| 5TF7 |
1.931 |
Nucleotide-binding domain 1 of the human cystic fibrosis transmembrane conductance regulator (CFTR) with ATP |
| 5TF8 |
1.861 |
Nucleotide-binding domain 1 of the human cystic fibrosis transmembrane conductance regulator (CFTR) with dTTP |
| 5TFA |
1.87 |
Nucleotide-binding domain 1 of the human cystic fibrosis transmembrane conductance regulator (CFTR) with dUTP |
| 5TFB |
1.87 |
Nucleotide-binding domain 1 of the human cystic fibrosis transmembrane conductance regulator (CFTR) with 7-methyl-GTP |
| 5TFC |
1.92 |
Nucleotide-binding domain 1 of the human cystic fibrosis transmembrane conductance regulator (CFTR) with GTP |
| 5TFD |
1.891 |
Nucleotide-binding domain 1 of the human cystic fibrosis transmembrane conductance regulator (CFTR) with CTP |
| 5TFF |
1.891 |
Nucleotide-binding domain 1 of the human cystic fibrosis transmembrane conductance regulator (CFTR) with UTP |
| 5TFG |
1.91 |
Nucleotide-binding domain 1 of the human cystic fibrosis transmembrane conductance regulator (CFTR) with 5-methyl-UTP |
| 5TFI |
1.891 |
Nucleotide-binding domain 1 of the human cystic fibrosis transmembrane conductance regulator (CFTR) with dGTP |
| 5TFJ |
1.85 |
Nucleotide-binding domain 1 of the human cystic fibrosis transmembrane conductance regulator (CFTR) with dCTP |
| 5TGK |
1.912 |
Nucleotide-binding domain 1 of the human cystic fibrosis transmembrane conductance regulator (CFTR) with dATP |
| 5UAK |
3.87 |
Dephosphorylated, ATP-free human cystic fibrosis transmembrane conductance regulator (CFTR) |
| 6GJQ |
2.49 |
human NBD1 of CFTR in complex with nanobody T27 |
| 6GJS |
1.95 |
Human NBD1 of CFTR in complex with nanobodies D12 and T4 |
| 6GJU |
2.6 |
human NBD1 of CFTR in complex with nanobodies T2a and T4 |
| 6GK4 |
2.91 |
Human NBD1 of CFTR in complex with nanobodies D12 and T8 |
| 6GKD |
2.99 |
human NBD1 of CFTR in complex with nanobodies D12 and G3a |
| 6HEP |
1.86 |
Crystal structure of human 14-3-3 beta in complex with CFTR R-domain peptide pS753-pS768 |
| 6MSM |
3.2 |
Phosphorylated, ATP-bound human cystic fibrosis transmembrane conductance regulator (CFTR) |
| 6O1V |
3.2 |
Complex of human cystic fibrosis transmembrane conductance regulator (CFTR) and GLPG1837 |
| 6O2P |
3.3 |
Complex of ivacaftor with cystic fibrosis transmembrane conductance regulator (CFTR) |
| 6UK1 |
2.693 |
Crystal structure of nucleotide-binding domain 2 (NBD2) of the human Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) |
| 6WBS |
1.857 |
Human CFTR first nucleotide binding domain with dF508/V510D |
| 6ZE1 |
2.705 |
human NBD1 of CFTR in complex with nanobody G11a |
| 7QI1 |
1.76 |
Crystal structure of human 14-3-3 protein beta in complex with CFTR peptide pS753pS768 and PPI stabilizer CY007424 |
| 7SV7 |
3.8 |
The complex of phosphorylated human cystic fibrosis transmembrane conductance regulator (CFTR) with ATP/Mg and Tezacaftor (VX-661) |
| 7SVD |
2.7 |
The complex of phosphorylated human cystic fibrosis transmembrane conductance regulator (CFTR) with ATP/Mg and Lumacaftor (VX-809) |
| 7SVR |
3.9 |
The complex of dephosphorylated human cystic fibrosis transmembrane conductance regulator (CFTR) and Lumacaftor (VX-809) |
| 8EIG |
3.6 |
The complex of phosphorylated human delta F508 cystic fibrosis transmembrane conductance regulator (CFTR) with elexacaftor (VX-445) and ATP/Mg |
| 8EIO |
2.8 |
The complex of phosphorylated human delta F508 cystic fibrosis transmembrane conductance regulator (CFTR) with elexacaftor (VX-445), lumacaftor (VX-809) and ATP/Mg |
| 8EIQ |
3.0 |
The complex of phosphorylated human delta F508 cystic fibrosis transmembrane conductance regulator (CFTR) with Trikafta [elexacaftor (VX-445), tezacaftor (VX-661), ivacaftor (VX-770)] and ATP/Mg |
| 8EJ1 |
6.9 |
Dephosphorylated human delta F508 cystic fibrosis transmembrane conductance regulator (CFTR) |
| 8FZQ |
4.3 |
Dehosphorylated, ATP-bound human cystic fibrosis transmembrane conductance regulator (CFTR) |
